3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Hematologic Neoplasms
2
Mature B-cell Neoplasms
1
Interventions
Cyclophosphamide
17
fludarabine
16
fludarabine phosphate
11
venetoclax
9
Azacitidine
9
Rituximab
8
Nivolumab
7
Melphalan
7
Tacrolimus
6
Cytarabine
6
Specimen Handling
5
Sirolimus
5
Ipilimumab
5
Clofarabine
5
CTLA-4 Antigen
5
Antilymphocyte Serum
5
belinostat
4
aldesleukin
4
Thiotepa
4
Standard of Care
4
Practice Guidelines as Topic
4
Mycophenolic Acid
4
Methotrexate
4
Magnetic Resonance Spectroscopy
4
Interleukin-2
4
Granulocyte Colony-Stimulating Factor
4
Dexamethasone
4
Busulfan
4
Bortezomib
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Neoplasms
×
ARQ531
×
Clear all
NCT05347225
2026-04-30
MK-1026-005
Merck Sharp & Dohme LLC
Phase 1
Active not recruiting
12 enrolled
NCT06586671
2024-09-19
MK-1026-007
Merck Sharp & Dohme LLC
Phase 1
Completed
40 enrolled